T(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: Report of a case treated with sorafenib and review of the literature

Leukemia Research

Volumn 35, Issue 9, 2011, Pages

  Wakim, Jad J ^a   Tirado, Carlos A ^a   Chen, Weina ^b   Collins, Robert ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b AmeriPath North Texas Hematopathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; HEMOGLOBIN; HYDROXYUREA; IDARUBICIN; PROTEIN TYROSINE KINASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SORAFENIB; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANTIGEN DETECTION; B LYMPHOBLAST; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; CELL EXPANSION; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 8; CYTOGENETICS; DEATH; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVITY; GENE REARRANGEMENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOPHENOTYPING; LETTER; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MYELOPROLIFERATIVE DISORDER; ONCOGENE; ONCOGENE BCR; ONCOGENE FGFR1; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SIDE EFFECT; SPLENOMEGALY; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 8; DIAGNOSIS, DIFFERENTIAL; HUMANS; MYELOPROLIFERATIVE DISORDERS; ONCOGENE PROTEINS, FUSION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-BCR; PYRIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; TRANSLOCATION, GENETIC;

EID: 80051474782     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.05.013     Document Type: Letter

References (11)

1. Macdonald D., Reiter A., Cross N.C. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 2002, 107(2):101-107.
2. Jackson C.C., Medeiros L.J., Miranda R.N. 8p11 myeloproliferative syndrome: a review. Hum Pathol 2010, 41(April (4)):461-476.
3. Baldazzi C., Iacobucci I., Luatti S., et al. B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. Leuk Res 2010, 34(October (10)):e282-285.
4. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(October (19)):7099-7109.
5. Demiroglu A., Steer E.J., Heath C., et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 2001, 98(December (13)):3778-3783.
6. Kawamoto H., Katsura Y. A new paradigm for hematopoietic cell lineages: revision of the classical concept of the myeloid-lymphoid dichotomy. Trends Immunol 2009, 30(May (5)):193-200.
7. Iacobucci I., Storlazzi C.T., Cilloni D., et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on beh alf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 2009, 114(September (10)):2159-2167.
8. Iacobucci I., Lonetti A., Paoloni F., et al. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on b ehalf of the GIMEMA Acute Leukemia Working Party. Haematologica 2010, 95(October (10)):1683-1690.
9. Richebourg S., Theisen O., Plantier I., et al. Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia. Genes Chromosomes Cancer 2008, 47(October (10)):915-918.
10. David M., Cross N.C., Burgstaller S., et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007, 109(January (1)):61-64.
11. Chen J., Deangelo D.J., Kutok J.L., et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A 2004, 101(October (40)):14479-14484.